Thursday Jul 3
Insider Selling: BioCryst Pharmaceuticals CFO Sells 3,125 Shares of Stock
BioCryst Pharmaceuticals CFO Thomas R. Staab II unloaded 3,125 shares of the stock on the open market in a transaction that occurred on Tuesday, July 1st.
BioCryst Pharmaceuticals CFO Thomas R. Staab II Sells 3,125 Shares
BioCryst Pharmaceuticals CFO Thomas R. Staab II sold 3,125 shares of the company's stock in a transaction that occurred on Monday, June 23rd.
BioCryst snags $1.9M for antiviral candidate
The Durham-based company, which is developing an antiviral dubbed BCX4430, had already partnered with the National Institute of Allergy and Infectious Diseases, receiving an initial award of $5 million last September.
NIAID exercises option under agreement with BioCryst
NIAID exercises option under agreement with BioCryst BioCryst Pharmaceuticals disclosed that on June 17 the company and the National Institute of Allergy and Infectious Diseases, or NIAID, amended their agreement dated September 12, 2013 for the development of BCX4430.
Public offering yields $115M for BioCryst
Thanks to a successful public offering, Durham-based BioCryst Pharmaceuticals has some additional cash to fund accelerated testing for one of its drugs.